CN101237872A - 噻托铵盐在治疗严重持续性哮喘中的用途 - Google Patents

噻托铵盐在治疗严重持续性哮喘中的用途 Download PDF

Info

Publication number
CN101237872A
CN101237872A CNA2006800288506A CN200680028850A CN101237872A CN 101237872 A CN101237872 A CN 101237872A CN A2006800288506 A CNA2006800288506 A CN A2006800288506A CN 200680028850 A CN200680028850 A CN 200680028850A CN 101237872 A CN101237872 A CN 101237872A
Authority
CN
China
Prior art keywords
treatment
asthma
patient
preparation
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800288506A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·恩格尔
斯蒂芬·海因里赫斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101237872(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN101237872A publication Critical patent/CN101237872A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2006800288506A 2005-08-06 2006-08-02 噻托铵盐在治疗严重持续性哮喘中的用途 Pending CN101237872A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107266 2005-08-06
EP05107266.8 2005-08-06

Publications (1)

Publication Number Publication Date
CN101237872A true CN101237872A (zh) 2008-08-06

Family

ID=35432680

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800288506A Pending CN101237872A (zh) 2005-08-06 2006-08-02 噻托铵盐在治疗严重持续性哮喘中的用途

Country Status (16)

Country Link
US (3) US20070032516A1 (enExample)
EP (1) EP1915158A1 (enExample)
JP (1) JP2009504604A (enExample)
KR (1) KR20080039974A (enExample)
CN (1) CN101237872A (enExample)
AR (1) AR055597A1 (enExample)
AU (1) AU2006277968A1 (enExample)
BR (1) BRPI0614394A2 (enExample)
CA (1) CA2617717C (enExample)
IL (1) IL189248A0 (enExample)
MX (1) MX2008001506A (enExample)
NZ (1) NZ566399A (enExample)
RU (1) RU2422144C2 (enExample)
TW (1) TWI409072B (enExample)
WO (1) WO2007017438A1 (enExample)
ZA (1) ZA200800186B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
WO2007077162A1 (en) * 2006-01-04 2007-07-12 Boehringer Ingelheim International Gmbh Use of tiotropium salts in the treatment of moderate persistent asthma
MX2012005711A (es) * 2009-11-17 2012-10-05 Cipla Ltd Soluciones de inhalacion.
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
US5888396A (en) * 1996-12-17 1999-03-30 Perriello; Felix Anthony Bioremediation of pollutants with butane-utilizing bacteria
US6156503A (en) * 1997-03-03 2000-12-05 The Regents Of The University Of California Diagnosing asthma patients predisposed to adverse β-agonist reactions
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
CA2425539C (en) * 2000-10-12 2007-04-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline monohydrate, processes for the preparation thereof and the use thereof for preparing a pharmaceutical composition
US6908928B2 (en) * 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
DE10216036A1 (de) * 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
WO2004014293A2 (en) * 2002-06-12 2004-02-19 Epigenesis Pharmaceuticals, Inc. Combination of anti-muscarinic agents and non-glucocorticoid steroids
EP1531866A1 (en) * 2002-08-29 2005-05-25 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
US7968717B2 (en) * 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
AU2006244683A1 (en) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
AU2006248189A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
US20070167480A1 (en) * 2005-12-19 2007-07-19 Sicor Inc. Pure and stable tiotropium bromide
WO2007077162A1 (en) 2006-01-04 2007-07-12 Boehringer Ingelheim International Gmbh Use of tiotropium salts in the treatment of moderate persistent asthma

Also Published As

Publication number Publication date
NZ566399A (en) 2011-07-29
CA2617717C (en) 2014-02-11
RU2422144C2 (ru) 2011-06-27
TW200744606A (en) 2007-12-16
US20130245059A1 (en) 2013-09-19
WO2007017438A1 (en) 2007-02-15
CA2617717A1 (en) 2007-02-15
RU2008108302A (ru) 2009-09-20
EP1915158A1 (en) 2008-04-30
ZA200800186B (en) 2009-04-29
IL189248A0 (en) 2008-08-07
KR20080039974A (ko) 2008-05-07
US20070032516A1 (en) 2007-02-08
AU2006277968A1 (en) 2007-02-15
MX2008001506A (es) 2008-04-07
BRPI0614394A2 (pt) 2011-03-29
AR055597A1 (es) 2007-08-29
TWI409072B (zh) 2013-09-21
JP2009504604A (ja) 2009-02-05
US20090163531A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
US9549936B2 (en) Method for preparing dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide
EA023839B1 (ru) Комбинации антагониста мускариновых рецепторов и агониста бета-2-адренорецепторов
CN103582477A (zh) 包含芜地溴铵和皮质类固醇的组合
US20150224090A1 (en) Use of tiotropium salts in the treatment of moderate persistent asthma
US20090163531A1 (en) Use of Tiotropium Salts in the Treatment of Severe Persistent Asthma
CN101426476A (zh) 具有高药物比例的吸入组合物
HK1126974A (en) Use of tiotropium salts in the treatment of moderate persistent asthma
AU2012258410B2 (en) Use of tiotropium salts in the treatment of severe persistant asthma
MX2008007568A (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
US20070072891A1 (en) Method for the Protection Against the Risk of Cardiac Disorders Comprising Administration of Tiotropium Salts
HK1174570B (en) Process for providing particles with reduced electrostatic charges
HK1174570A1 (en) Process for providing particles with reduced electrostatic charges
HK1160601A (en) Inhalation composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080806